Acne

Atrisone completes pivotal phase III studies

Published in Drug Week, February 6th, 2004

Atrix Laboratories, Inc., (ATRX) announced that the company's proprietary acne drug, Atrisone (5% topical dapsone gel) has successfully completed two pivotal phase III clinical efficacy studies.

More than 3000 patients were enrolled in these double-blind, randomized, vehicle-controlled studies, which were conducted in more than 100 centers around the U.S. and Canada.

"We are pleased to announce the successful completion of the largest clinical studies ever undertaken by this company," said Steve Garrett, senior vice president of clinical research. "The databases have been locked, and preliminary data analyses are complete. We will be working...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-02-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry